RecruitingNot ApplicableNCT06973031

A Prospective Clinical Study to Evaluate the Safety and Effectiveness of Pulmonary Vein Isolation Plus Box Isolation of Fibrotic Areas With the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation


Sponsor

Kardium Inc.

Enrollment

115 participants

Start Date

Jun 10, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The study will evaluate the safety and 12-month effectiveness of the Pulmonary Vein Isolation plus Box Isolation of Fibrotic Areas (BIFA) ablation strategy with the Globe Pulsed Field System (Globe PF System) for the treatment of atrial fibrillation.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria2

  • A diagnosis of recurrent symptomatic paroxysmal or persistent AF
  • Failure or intolerance of at least one antiarrhythmic drug (AAD) Class I or III

Exclusion Criteria10

  • Long-standing persistent AF (sustained \>12 months)
  • Atrial fibrillation secondary to a reversible cause or of non-cardiac origin
  • History of thromboembolic events within the past six months
  • Myocardial infarction (MI)/percutaneous coronary intervention (PCI) within the last three months
  • Any cardiac surgery within the previous six months
  • Prior left atrial ablation or surgical procedure
  • Presence of an implanted cardiac device
  • Body mass index (BMI) \>40 kg/m\^2
  • Left ventricular ejection fraction (LVEF) \<35%
  • Anterior-posterior left atrial (LA) diameter \>55mm

Interventions

DEVICEGlobe Pulsed Field System

Ablation and atrial mapping with the Globe Pulsed Field System


Locations(1)

Westpfalz-Klinikum GmbH Kaiserslautern

Kaiserslautern, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06973031


Related Trials